Supernus sets IPO terms ahead of epilepsy drugs' US approvals
This article was originally published in Scrip
Executive Summary
In its second attempt at an initial public offering since December 2010, Supernus Pharmaceuticals Inc. priced an IPO at $12 to $14 per share to generate up to $92.9 million before fees to advance the company's pipeline of neurology and psychiatry drugs for epilepsy and attention deficit hyperactivity disorder (ADHD).